Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry

Steg, Philippe Gabriel; Alam, Samir; Chiang, Chern‐En; Gamra, Habib; Goethals, Marnix; Inoue, Hiroshi; Krapf, Laura; Lewalter, Thorsten; Merioua, Ihsen; Murı́n, J; Naditch-Brûlé, Lisa; Ponikowski, Piotr; Rosenqvist, Mårten; Silva-Cardoso, José; Zharinov, O.; Brette, Sandrine; Neill, James O; investigators, RealiseAF

doi:10.1136/heartjnl-2011-300550

Cited by 111 publications

(117 citation statements)

References 36 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Występują u nich różne objawy, w tym osłabienie, kołatanie serca, duszność, ucisk w klatce piersiowej, zaburzenia snu oraz dystres psychospołeczny [32,[177][178][179][180]. Poprawę jakości życia stwierdzono pod wpły-wem zarówno farmakoterapii, jak i leczenia interwencyjnego [181][182][183][184][185], ale dostępne są jedynie ograniczone dane porównawcze na temat korzyści z różnych metod leczenia [32,186].…”

Section: Nasilenie Objawów Związanychunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,380

4,206

View full text Add to dashboard Cite

Section: Nasilenie Objawów Związanychunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,380

4,206

View full text Add to dashboard Cite

“…9 Population characteristics were summarized as mean and SD for continuous variables and as count and percentages for qualitative variables. Comparisons between subgroups were made using the χ 2 test, Fisher exact test for nominal variables, trend test for ordinal variables, or ANOVA for quantitative variables.…”

Section: Discussionmentioning

confidence: 99%

“…As previously published, 9 RealiseAF was a cross-sectional observational survey of >10 000 patients with AF seen at >800 sites in 26 countries from October 2009 to May 2010. Participating countries were Algeria, Azerbaijan, Belgium, Bulgaria, Czech Republic, Egypt, Germany, Hungary, India, Ireland, Italy, Lebanon, Lithuania, Mexico, Morocco, Portugal, Russia, Slovakia, Spain, Sweden, Switzerland, Taiwan, Tunisia, Turkey, Ukraine, and Venezuela.…”

Section: Designmentioning

confidence: 99%

Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice

Chiang

Naditch-Brûlé²,

Murı́n³

et al. 2012

Circ: Arrhythmia and Electrophysiology

Self Cite

270

102

View full text Add to dashboard Cite

Background— There is a paucity of international data on the various types of atrial fibrillation (AF) outside the highly selected populations from randomized trials. This study aimed to describe patient characteristics, risk factors, comorbidities, symptoms, management strategy, and control of different types of AF in real-life practice. Methods and Results— Real-life global survey evaluating patients with atrial fibrillation (RealiseAF) was a contemporary, large-scale, cross-sectional international survey of patients with AF who had ≥1 episode in the past 12 months. Investigators were randomly selected to avoid bias. Among 9816 eligible patients from 831 sites in 26 countries, 2606 (26.5%) had paroxysmal, 2341 (23.8%) had persistent, and 4869 (49.6%) had permanent AF. As AF progressed from paroxysmal to persistent and permanent forms, the prevalence of comorbidities, such as heart failure (32.9%, 44.3%, and 55.6%), coronary artery disease (30.0%, 32.9%, and 34.3%), cerebrovascular disease (11.7%, 10.8%, and 17.6%), and valvular disease (16.7%, 21.2%, and 35.8%), increased, and the prevalence of lone AF decreased. Similarly, there was an increase in mean CHADS 2 [cardiac failure, hypertension, age, diabetes, stroke (doubled)] score (1.7, 1.8, and 2.2), and more than half of patients (51.0%, 56.7%, and 67.3%) qualified for oral anticoagulants. Almost 90% of patients received ≥1 antiarrhythmic drug, but >60% had European Heart Rhythm Association symptom scores from II to IV. Furthermore, 40.7% of persistent and 49.8% of permanent AF patients were still in AF with a heart rate >80 beats per minute. Conclusions— This survey disclosed high cardiovascular risks and an unmet need in daily practice for patients with any type of AF, especially those with the permanent form.

show abstract

“…In the Euro Heart survey9 and RealiseAF study,11 diagnosis of AF was distributed 28% and 25% paroxysmal, 22% and 22% persistent and 29% and 46% permanent AF, respectively. In our study, more patients had diagnoses of paroxysmal (36%) and fewer of persistent AF (7%), similar to the EPHA registry (38% paroxysmal and 10% persistent AF) 12.…”

Section: Discussionmentioning

confidence: 99%

“…The Euro Heart Survey described the management of AF across 35 European countries in 2003–2004, in terms of diagnostic tests, interventions and drugs 9. Recently, the RecordAF Study,10 RealiseAF,11 EHPA12 and GARFIELD13 Registries have provided further insights into the management of AF in normal clinical practice. These multinational registries are valuable but include a variety of models of healthcare provision across Europe.…”

Section: Introductionmentioning

confidence: 99%

Current management of atrial fibrillation: an observational study in NHS primary care

Kassianos¹,

Arden²,

Hogan

et al. 2013

BMJ Open

View full text Add to dashboard Cite

ObjectiveTo describe National Health Service (NHS) resource use and pharmacological management of atrial fibrillation (AF) in routine UK primary care.DesignMulticentre retrospective study.SettingSeven primary care practices in England, one in Wales.PatientsPatients with AF were identified and approached for consent. Data were collected on the first 12 weeks post-diagnosis (‘initiation’) and, for established patients, up to the most recent 3 years of management (‘maintenance’).ResultsData collected on 825 patients with AF, 56% men. Mean age (at diagnosis) 70.5 years. Mean 2.4 (SD 2.2) visits to primary care per patient during the initiation phase; 1.5 (SD 1.8) per patient-year during the maintenance phase. Mean 0.4 (SD 0.6) inpatient admissions for AF per patient during the initiation phase and 0.1 (SD 0.3) per patient-year during the maintenance phase. The mean length of hospital stay per admitted patient was 5.6 days during initiation and 6.4 days per patient-year during maintenance. During the initiation phase, 46.1% (143/310) patients received a β-blocker and 97 (31.3%) received no rate/rhythm control. Only 234 (75.5%) patients received thromboprophylaxis in the 12 weeks postdiagnosis and 674 (87.7%) in the maintenance phase. 440 (57.2%) patients were deemed to be at high risk of stroke at the end of the maintenance phase; 55% (242/440) of these were receiving appropriate anticoagulation therapy.ConclusionsThe results suggest that there are opportunities for optimisation of treatment and there is significant NHS resource associated with AF management, the details of which are invaluable for future healthcare planning and policy development in this area.

show abstract

Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry

Cited by 111 publications

References 36 publications

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice

Current management of atrial fibrillation: an observational study in NHS primary care

Contact Info

Product

Resources

About